Elekta AB (publ)
STO:EKTA B

Watchlist Manager
Elekta AB (publ) Logo
Elekta AB (publ)
STO:EKTA B
Watchlist
Price: 60.9 SEK 0.74% Market Closed
Market Cap: 23.3B SEK
Have any thoughts about
Elekta AB (publ)?
Write Note

Elekta AB (publ)
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Elekta AB (publ)
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Elekta AB (publ)
STO:EKTA B
Accounts Payable
kr1.6B
CAGR 3-Years
15%
CAGR 5-Years
2%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Accounts Payable
kr45.6m
CAGR 3-Years
15%
CAGR 5-Years
17%
CAGR 10-Years
12%
Getinge AB
STO:GETI B
Accounts Payable
kr2.4B
CAGR 3-Years
18%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Accounts Payable
kr612m
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Sedana Medical AB (publ)
STO:SEDANA
Accounts Payable
kr4m
CAGR 3-Years
-33%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

Elekta AB (publ)
Glance View

Market Cap
23.3B SEK
Industry
Health Care

Elekta AB emanates sophistication and precision, standing at the forefront of medical technology. Established in 1972 by Lars Leksell, the Swedish innovator manifests a legacy deeply rooted in advancing oncology and neurosurgery treatment solutions. Elekta's forte lies in crafting state-of-the-art equipment and software that assist medical practitioners in treating complex cancers and brain disorders. Their products, such as the Leksell Gamma Knife and various advanced linear accelerators, showcase their commitment to minimally invasive treatment. By developing cutting-edge systems that refine radiation therapy and radio-surgery, Elekta plays a pivotal role in enhancing patient outcomes, offering more precise targeting of tumors with minimal damage to surrounding healthy tissues. Financially, Elekta thrives through a multi-faceted revenue model that harmoniously blends hardware sales with recurring income from maintenance services, software upgrades, and training. Their business strategy capitalizes on long-term relationships with healthcare providers, ensuring a steady demand for both product innovation and servicing their existing installations. By anchoring its revenue stream in this hybrid fashion, Elekta offers a compelling proposition for shareholders—a blend of resilient cash flow dynamics and growth through groundbreaking technological advancements. As the global healthcare landscape evolves, Elekta's continuous investment in research and development ensures they remain a venerated leader in tackling the world's challenges in cancer care and neurological disorders.

EKTA B Intrinsic Value
96.61 SEK
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Elekta AB (publ)'s Accounts Payable?
Accounts Payable
1.6B SEK

Based on the financial report for Apr 30, 2024, Elekta AB (publ)'s Accounts Payable amounts to 1.6B SEK.

What is Elekta AB (publ)'s Accounts Payable growth rate?
Accounts Payable CAGR 5Y
2%

Over the last year, the Accounts Payable growth was -14%. The average annual Accounts Payable growth rates for Elekta AB (publ) have been 15% over the past three years , 2% over the past five years .

Back to Top